Skip to content

company

Merck

Global pharmaceutical company, known as MSD outside the US/Canada, maker of cancer drug Keytruda and a broad portfolio of vaccines and medicines.

Known aliases

  • Merck & Co.
  • MRK
  • MSD

Relationships

No evidence-backed relationships are recorded.

Current stories

invest6 publishers

Moderna doubles on a Phase 3 win whose effect size has not been published yet

Intismeran autogene plus Keytruda beat Keytruda alone in resected melanoma. The market added roughly $35bn to Moderna on a result the companies described only in adjectives.

Perspective Coverage

6 publishers
Builder
Builder 29%
Operator
Operator 25%
Investor
Investor 46%

Reality

Evidence45
Adoption5
Hype gap+55
Incentives70
Confidence60
product3 publishers

Moderna's per-patient cancer vaccine cleared Phase 3. Now it is a manufacturing problem.

Intismeran autogene met both primary endpoints in a 1,137-patient melanoma trial. Every dose is built from one tumour's sequence, which turns approval into a question about process, not product.

Perspective Coverage

3 publishers
Builder
Builder 38%
Operator
Operator 42%
Investor
Investor 20%

Reality

Evidence40
Adoption5
Hype gap+40
Incentives75
Confidence55
science4 publishers

Merck and Moderna clear the Phase 3 bar on a personalized cancer vaccine, minus the numbers

The companies say intismeran plus Keytruda slowed melanoma's return after surgery in the first randomized Phase 3 test of neoantigen vaccines. No detailed data has been released.

Perspective Coverage

4 publishers
Builder
Builder 39%
Operator
Operator 36%
Investor
Investor 25%

Reality

Evidence40
Adoption3
Hype gap+40
Incentives70
Confidence55